FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313857557> ?p ?o ?g. }

• W4313857557 endingPage "310" @default.
• W4313857557 startingPage "303" @default.
• W4313857557 abstract "Selinexor [Nexpovio® (EU); Xpovio® (USA)] is a first-in-class, selective exportin-1 inhibitor. Oral selinexor once weekly in combination with subcutaneous bortezomib once weekly and oral dexamethasone twice weekly (selinexor–bortezomib–dexamethasone) is approved in the EU and USA for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In the open-label, randomized, phase 3 BOSTON trial, this regimen significantly prolonged progression-free survival (PFS) compared with the standard bortezomib–dexamethasone regimen in patients with previously treated multiple myeloma. Selinexor–bortezomib–dexamethasone had a generally manageable tolerability profile and an acceptable safety profile in BOSTON, with a lower incidence of peripheral neuropathy (a bortezomib-induced toxicity) compared with bortezomib–dexamethasone. The triplet regimen uses less bortezomib and dexamethasone during the first 24 weeks of treatment. The efficacy and safety profiles of selinexor–bortezomib–dexamethasone, combined with its once-weekly administration of selinexor and bortezomib, make it a useful additional triplet therapy option for previously treated multiple myeloma. Despite the availability of several drug classes, relapse and refractoriness is common in multiple myeloma. Selinexor [Nexpovio® (EU); Xpovio® (USA)] is an oral drug that selectively inhibits exportin-1, a nuclear exporter protein overexpressed in many cancer cells. Selinexor-bortezomib-dexamethasone is approved in the EU and USA for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In the pivotal BOSTON trial, the triplet regimen significantly prolonged PFS compared with standard bortezomib-dexamethasone regimen in patients with previously treated multiple myeloma, with a generally manageable tolerability profile and an acceptable safety profile. Selinexor-bortezomib-dexamethasone uses less bortezomib and dexamethasone versus standard bortezomib-dexamethasone regimen. Therefore, selinexor-bortezomib-dexamethasone is a useful additional triple treatment option for previously treated multiple myeloma." @default.
• W4313857557 created "2023-01-10" @default.
• W4313857557 creator A5077298201 @default.
• W4313857557 date "2023-01-09" @default.
• W4313857557 modified "2023-09-29" @default.
• W4313857557 title "Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma" @default.
• W4313857557 cites W1869200070 @default.
• W4313857557 cites W2094088075 @default.
• W4313857557 cites W2159089429 @default.
• W4313857557 cites W2528174730 @default.
• W4313857557 cites W2543797757 @default.
• W4313857557 cites W2772881286 @default.
• W4313857557 cites W2794340145 @default.
• W4313857557 cites W2804787940 @default.
• W4313857557 cites W2897241170 @default.
• W4313857557 cites W2938300809 @default.
• W4313857557 cites W2969931905 @default.
• W4313857557 cites W2970420607 @default.
• W4313857557 cites W3008231845 @default.
• W4313857557 cites W3105812043 @default.
• W4313857557 cites W3127065235 @default.
• W4313857557 cites W3134103265 @default.
• W4313857557 cites W3154559926 @default.
• W4313857557 cites W3157642871 @default.
• W4313857557 cites W3165381538 @default.
• W4313857557 cites W3170192715 @default.
• W4313857557 cites W3176714232 @default.
• W4313857557 cites W3188660209 @default.
• W4313857557 cites W3212572680 @default.
• W4313857557 cites W4210281651 @default.
• W4313857557 cites W4225844279 @default.
• W4313857557 cites W4282966692 @default.
• W4313857557 cites W4298143191 @default.
• W4313857557 doi "https://doi.org/10.1007/s11523-022-00945-3" @default.
• W4313857557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36622630" @default.
• W4313857557 hasPublicationYear "2023" @default.
• W4313857557 type Work @default.
• W4313857557 citedByCount "1" @default.
• W4313857557 countsByYear W43138575572023 @default.
• W4313857557 crossrefType "journal-article" @default.
• W4313857557 hasAuthorship W4313857557A5077298201 @default.
• W4313857557 hasBestOaLocation W43138575572 @default.
• W4313857557 hasConcept C126322002 @default.
• W4313857557 hasConcept C143998085 @default.
• W4313857557 hasConcept C197934379 @default.
• W4313857557 hasConcept C2776364478 @default.
• W4313857557 hasConcept C2777478702 @default.
• W4313857557 hasConcept C2778367456 @default.
• W4313857557 hasConcept C2778375690 @default.
• W4313857557 hasConcept C2780401358 @default.
• W4313857557 hasConcept C2781413609 @default.
• W4313857557 hasConcept C71924100 @default.
• W4313857557 hasConcept C98274493 @default.
• W4313857557 hasConceptScore W4313857557C126322002 @default.
• W4313857557 hasConceptScore W4313857557C143998085 @default.
• W4313857557 hasConceptScore W4313857557C197934379 @default.
• W4313857557 hasConceptScore W4313857557C2776364478 @default.
• W4313857557 hasConceptScore W4313857557C2777478702 @default.
• W4313857557 hasConceptScore W4313857557C2778367456 @default.
• W4313857557 hasConceptScore W4313857557C2778375690 @default.
• W4313857557 hasConceptScore W4313857557C2780401358 @default.
• W4313857557 hasConceptScore W4313857557C2781413609 @default.
• W4313857557 hasConceptScore W4313857557C71924100 @default.
• W4313857557 hasConceptScore W4313857557C98274493 @default.
• W4313857557 hasIssue "2" @default.
• W4313857557 hasLocation W43138575571 @default.
• W4313857557 hasLocation W43138575572 @default.
• W4313857557 hasLocation W43138575573 @default.
• W4313857557 hasOpenAccess W4313857557 @default.
• W4313857557 hasPrimaryLocation W43138575571 @default.
• W4313857557 hasRelatedWork W2000246028 @default.
• W4313857557 hasRelatedWork W2056686464 @default.
• W4313857557 hasRelatedWork W2058808800 @default.
• W4313857557 hasRelatedWork W2072994817 @default.
• W4313857557 hasRelatedWork W2362636202 @default.
• W4313857557 hasRelatedWork W2366030768 @default.
• W4313857557 hasRelatedWork W2427804748 @default.
• W4313857557 hasRelatedWork W3134875278 @default.
• W4313857557 hasRelatedWork W4241469660 @default.
• W4313857557 hasRelatedWork W4313857557 @default.
• W4313857557 hasVolume "18" @default.
• W4313857557 isParatext "false" @default.
• W4313857557 isRetracted "false" @default.
• W4313857557 workType "article" @default.